Apellis Pharmaceuticals, Inc. (APLS) has a consensus analyst rating of Buy, based on 25 analysts covering the stock. Of those, 18 recommend buying, 6 recommend holding, and 1 recommend selling.
The analyst consensus price target for APLS is $33.50, representing a -18.0% downside from the current price of $40.85. Price targets range from a low of $19.00 to a high of $52.00.
